Fry J A, Grines C L
Department of Cardiology, William Beaumont Hospital, Royal Oak, Michigan 48074, USA.
Semin Interv Cardiol. 2000 Sep;5(3):117-28.
Percutaneous coronary intervention produces vessel wall injury and activation of platelets that are responsible for producing peri-procedural ischemic complications. The importance of adequate antiplatelet therapy during coronary intervention to reduce platelet mediated ischaemic complications has been recognized for some time. Until recently, adjunctive treatment with aspirin was the only available antiplatelet therapy after coronary intervention that had demonstrated benefit. During the last decade, newer and more potent agents have demonstrated consistent reductions in ischaemic events after intervention and appear to have some enduring effect. Additionally, optimization of antiplatelet therapy with aspirin and the thienopyridines after coronary stenting has been an important advance allowing for the current liberal use of coronary stents.
经皮冠状动脉介入治疗会造成血管壁损伤并激活血小板，而这正是导致围手术期缺血性并发症的原因。冠状动脉介入治疗期间充分的抗血小板治疗对于减少血小板介导的缺血性并发症的重要性，人们已经认识了一段时间。直到最近，阿司匹林辅助治疗仍是冠状动脉介入治疗后唯一已证实有益的抗血小板治疗方法。在过去十年中，更新、更强效的药物已证实可持续减少介入治疗后的缺血事件，并且似乎有一定的持久效果。此外，冠状动脉支架置入术后使用阿司匹林和噻吩吡啶优化抗血小板治疗是一项重要进展，使得目前能够广泛使用冠状动脉支架。
